Metis TechBio Management
Management criteria checks 1/4
Metis TechBio's CEO is Chris Lai, appointed in Feb 2020, has a tenure of 6.42 years. total yearly compensation is CN¥58.69M, comprised of 5.2% salary and 94.8% bonuses, including company stock and options. directly owns 10.53% of the company’s shares, worth €136.78M. The average tenure of the management team and the board of directors is 2 years and 2.8 years respectively.
Key information
Chris Lai
Chief executive officer
CN¥58.7m
Total compensation
| CEO salary percentage | 5.16% |
| CEO tenure | 6.4yrs |
| CEO ownership | 10.5% |
| Management average tenure | 2yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | CN¥59m | CN¥3m | -CN¥392m |
| Sep 30 2025 | n/a | n/a | -CN¥369m |
| Dec 31 2024 | CN¥53m | CN¥1m | -CN¥499m |
| Dec 31 2023 | CN¥42m | CN¥1m | -CN¥582m |
Compensation vs Market: Chris's total compensation ($USD8.66M) is above average for companies of similar size in the German market ($USD1.81M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Lai (37 yo)
Dr. Tsai-Ta Lai, also known as Chris, is Co-founder of Metis Techbio Co., LTD and has been its Chief Executive Officer since February 12, 2020. Dr. Lai is the Chairman of the Board of Metis Techbio Co. LTD...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 6.4yrs | CN¥58.69m | 10.53% € 136.8m | |
| Co-founder | 6.4yrs | CN¥35.48m | 3.03% € 39.4m | |
| Co-founder | no data | CN¥32.85m | 5.81% € 75.4m | |
| CFO & Board secretary | 1.3yrs | no data | no data | |
| VP & Head of Technology | no data | no data | no data | |
| Chief Scientific Officer | 2.6yrs | no data | no data | |
| Chief Business Officer | 1.5yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
Experienced Management: RO9's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 6.8yrs | CN¥58.69m | 10.53% € 136.8m | |
| Co-founder | 6.8yrs | CN¥35.48m | 3.03% € 39.4m | |
| Co-founder | no data | CN¥32.85m | 5.81% € 75.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-executive Director | 2.9yrs | no data | no data | |
| Independent Non-executive Director | less than a year | no data | no data | |
| Independent Non-executive Director | less than a year | no data | no data | |
| Independent Non-executive Director | less than a year | no data | no data | |
| Non-executive Director | 2.8yrs | no data | no data |
Experienced Board: RO9's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 14:43 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metis TechBio Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wing-Tai Ng | Deutsche Bank |
| Cui Cui | Jefferies LLC |